The effect of estrogen on T lymphocyte immunoregulation in mice with hypertrophic cardiomyopathy

doi:10.3877/cma.j.issn.2095-8757.2014.01.006

Abstract

Abstract:

Objective

To investigate the effect of the estrogenfor on T lymphocyte immunoregulation in mice with hypertrophic cardiomyopathy caused by AngⅡ.

Methods

Thirty one female C57BL/6 mice between 8~10 weeks were randomly divided into 4 groups: Sham (n=8), Sham+ AngⅡ (n=7), Ovx (n=8), Ovx+ AngⅡ (n=8). Osmotic mini-pumps containing AngⅡ (1000 ng·kg^-1·d^-1) were implanted subcutaneously in experimental mice. Thirty days after mini-pump implantation, blood pressure and heart rate were measured noninvasively in conscious animals by the tail-cuff method. Transthoracic echocardiography was performed under light sedation with 1.0% isoflurane. Ejection fraction(EF), fractional shortening(FS), diastolic/systolic ventricular septal (IVSd/IVSs) and posterior wall thickness (LVPWTd/LVPWTs), left ventricular diastolic and systolic volumes (LV VOLd/LV VOLs) were measured before and at the second, third, fourth, fifth week after the treatment. The immunologic markers of T cells CD3⁺ , CD4⁺ , CD8⁺ were analyzed by multicolor flow cytometry.

Results

The hypertension and hypertrophic cardiomyopathy model was set up in the mice by infusion of AngⅡ (1000 ng/kg per day). Each time point after modeling, Sham+ AngⅡ group showed significantly higher systolic blood pressure than in the sham group, Ovx+ AngⅡ group increased in systolic blood pressure compared with Ovx group. There were significant difference (F=15.23, P<0.01). Compared with the Sham group, Sham+ AngⅡ group indicated significantly increased IVSs, IVSd, LVPWs, LVPWd (t=3.81、7.74、3.87、7.73, P<0.01); Compared with Ovx, Ovx+ AngⅡ group showed significantly increased IVSs, IVSd, LVPWs, LVPWd and significantly reduced LV VOLs, LV VOLd (t=8.64、6.01、4.93、8.59、-2.16、-2.58, P<0.05 or 0.01). Compared to Sham and Ovx group, sham+ AngⅡ and Ovx+ AngⅡ group had the higher percentage of T cell ratios with reduced CD4⁺ and increased CD8⁺ cells (t=6.24、-4.85、7.70、-10.62、2.13、-11.04、11.11、-24.24, P<0.05 or 0.01); But compared with the sham+ Ang group, Ovx+ Ang group percentage of total T cells decrease with higher CD4⁺ ratio and lower CD8⁺ proportions (t=-2.78、3.37、-3.42、3.16, P<0.05 or 0.01).

Conclusion

Our studies shows that estrogen plays an important role in T cellimmunoregulationfor in AngⅡ-induced hypertrophic cardiomyopathy.

Key words: Estrogen s, Angiotensin Ⅱ, Hypertension, Cardiomyopathy, hypertrophic, Mice

Zhengxia Liu, Shikun Cai, Ping Zhou, Ying Liu, Xiang Lu. The effect of estrogen on T lymphocyte immunoregulation in mice with hypertrophic cardiomyopathy[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2014, 01(01): 19-23.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2014.01.006

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2014/V01/I01/19

Figures/Tables 4

References 24

[1]	Harrison DG. The immune system in hypertension[J]. Trans Am Clin Climatol Assoc，2014，125：130-138.
[2]	Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events[J]. JAMA，2004，292(19)：2343-2349.
[3]	Heymans S. Inflammation and cardiac remodeling during viral myocarditis[J]. Ernst Schering Res Found Workshop，2006，55：197-218.
[4]	Sasamura H, Azegami T, Itoh H. Current status of vaccination therapy for hypertension[J]. Nihon Rinsho, 2012，70(9)：1627-1632.
[5]	Zeymer U, Dechend R, Deeg E, et al. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry[J]. Int J Clin Pract，2012，66(3)：251-261.
[6]	Hoch NE, Guzik TJ, Chen W, et al. Regulation of T-cell function by endogenously produced angiotensin Ⅱ[J]. Am J Physiol Regul Integr Comp Physiol，2009, 296(2)：R208-216.
[7]	Eckel RH, Wassef M, Chait A, et al. Prevention conference Ⅵ：diabetes and cardiovascular disease: Writing Group Ⅱ：pathogenesis of atherosclerosis in diabetes[J]. Circulation，2002，105(18)：e138-143.
[8]	Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future[J]. Circulation，1999，99(8)：1091-1100.
[9]	Dzielak DJ. The immune system and hypertension[J]. Hypertension，1992，19(1 Suppl)：136-144.
[10]	Rosskopf D, Hartung K, Hense J, et al. Enhanced immunoglobulin formation of immortalized B cells from hypertensive patients[J]. Hypertension，1995，26(3)：432-435.
[11]	Harrison DG, Vinh A, Lob H, et al. Role of the adaptive immune system in hypertension[J]．Curr Opin Pharmacol，2010，10(2)：203-207.
[12]	Collett JA, Hart AK, Patterson E, et al. Renal angiotensin Ⅱ type 1 receptor expression and associated hypertension in rats with minimal SHR nuclear genome[J]. Physiol Rep，2013，1(5)：e00104.
[13]	Blagonravov ML, Frolov VA, Azova MM, et al. Characteristics of circadian rhythm of blood pressure during long-term hypertension development in SHR rats[J]. Bull Exp Biol Med，2013，155(5)：612-614.
[14]	Shao J, Nangaku M, Miyata T, et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury[J]. Hypertension，2003，42(1)：31-38.
[15]	Priyanka HP, Krishnan HC, Singh RV, et al. Estrogen modulates in vitro T cell responses in a concentration-and receptor-dependent manner: effects on intracellular molecular targets and antioxidant enzymes[J]. Mol Immunol，2013，56(4)：328-339.
[16]	Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach[J]. Cardiovasc Pathol，2004，13(3)：125-138.
[17]	Heymans S, Pauschinger M, De Palma A, et al. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis[J]. Circulation，2006，114(6)：565-573.
[18]	Li YY, Feng YQ, Kadokami T, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy[J]. Proc Natl Acad Sci USA，2000，97(23)：12746-12751.
[19]	Ishibashi M, Hiasa K, Zhao Q, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling[J]. Circ Res，2004，94(9)：1203-1210.
[20]	Mendelsohn ME. Protective effects of estrogen on the cardiovascular system[J]. Am J Cardiol，2002，89(12A)：12E-17E；discussion 17E-18E.
[21]	Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system[J]. N Engl J Med，1999，340(23)：1801-1811.
[22]	Bourassa PA, Milos PM, Gaynor BJ, et al. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice[J]. Proc Natl Acad Sci USA，1996，93(19)：10022-10027.
[23]	Arnal JF, Gourdy P, Garmy-Susini B, et al. Usefulness of experimental models to understand the vascular effects of estrogens[J]. Med Sci (Paris)，2003，19(12)：1226-1232.
[24]	Arnal JF, Scarabin PY, Trémollières F, et al. Estrogens in vascular biology and disease: where do we stand today[J]? Curr Opin Lipidol，2007，18(5)：554-560.

组别	n	EF(%)	FS(%)	IVSs(cm)	IVSd(cm)	LVPWs(cm)	LVPWd(cm)	LV VOLs(ml)	LV VOLd(ml)
Sham组	8	67.15±2.53	36.37±1.96	1.11±0.10	0.66±0.06	1.17±0.08	0.69±0.06	162.9±31.1	494.7±81.5
Sham＋AngⅡ组	7	69.06±6.49	37.94±5.21	1.38±0.17^a	0.94±0.08^a	1.35±0.10^a	0.93±0.06^a	136.3±52.0	431.0±103.6
Ovx组	8	68.90±5.06	37.94±4.14	1.12±0.06	0.69±0.05	1.15±0.09	0.71±0.06	162.6±36.4	520.8±67.0
Ovx＋AngⅡ组	8	74.14±8.02	42.38±6.5	1.53±0.12^cd	1.02±0.03^cd	1.47±0.16^cd	0.99±0.07^cd	113.8±52.4^b	422.6±84.2^b

组别	n	EF(%)	FS(%)	IVSs(cm)	IVSd(cm)	LVPWs(cm)	LVPWd(cm)	LV VOLs(ml)	LV VOLd(ml)
Sham组	8	67.15±2.53	36.37±1.96	1.11±0.10	0.66±0.06	1.17±0.08	0.69±0.06	162.9±31.1	494.7±81.5
Sham＋AngⅡ组	7	69.06±6.49	37.94±5.21	1.38±0.17^a	0.94±0.08^a	1.35±0.10^a	0.93±0.06^a	136.3±52.0	431.0±103.6
Ovx组	8	68.90±5.06	37.94±4.14	1.12±0.06	0.69±0.05	1.15±0.09	0.71±0.06	162.6±36.4	520.8±67.0
Ovx＋AngⅡ组	8	74.14±8.02	42.38±6.5	1.53±0.12^cd	1.02±0.03^cd	1.47±0.16^cd	0.99±0.07^cd	113.8±52.4^b	422.6±84.2^b

组别	只数	CD3^＋(%)	CD4^＋(%)	CD8^＋(%)	CD4^＋/CD8^＋
Sham组	8	17.24±6.04	71.39±9.01	21.61±2.21	3.31±0.37
Sham＋AngⅡ组	7	42.63±9.55^a	45.53±11.64^a	53.05±11.37^a	0.95±0.49^a
Ovx组	8	20.27±2.23	81.23±2.40	18.24±2.74	38.26±4.30
Ovx＋AngⅡ组	8	28.24±10.36^bc	60.59±4.71^bd	38.26±4.30^bd	1.61±0.31^bd

组别	只数	CD3^＋(%)	CD4^＋(%)	CD8^＋(%)	CD4^＋/CD8^＋
Sham组	8	17.24±6.04	71.39±9.01	21.61±2.21	3.31±0.37
Sham＋AngⅡ组	7	42.63±9.55^a	45.53±11.64^a	53.05±11.37^a	0.95±0.49^a
Ovx组	8	20.27±2.23	81.23±2.40	18.24±2.74	38.26±4.30
Ovx＋AngⅡ组	8	28.24±10.36^bc	60.59±4.71^bd	38.26±4.30^bd	1.61±0.31^bd

Please choose a citation manager

Content to export